Estimates Revisions Galapagos NV Sao Paulo
Stocks
G1LP34
BRG1LPBDR002
Biotechnology & Medical Research
|
Market Closed -
Sao Paulo
14:34:03 2026-09-10 EDT
|
5-day change | 1st Jan Change | ||
| 6.910 BRL | -1.57% |
|
+17.59% | -24.73% |
| 08-25 | Lakefront Biotherapeutics, Gilead Secure Another Orphan Drug Designation for Skin Disorder Drug in US | MT |
| 08-24 | Lakefront Gets FDA Orphan Drug Label for Gamgertamig | MT |
Turnover - Evolution of Analysts' Estimates
Earnings Per Share (EPS) - Evolution of Analysts' Estimates
Data source:
Lakefront Biotherapeutics NV(LKFT)
EBIT - Evolution of Analysts' Estimates
Dividend / Share (DPS) - Evolution of Analysts' Estimates
Data source:
Lakefront Biotherapeutics NV(LKFT)
Cash or Net Debt - Evolution of Analysts' Estimates
| 1m. Revenue rev. | 1y. Revenue rev. | 1y. EPS revision | ||
|---|---|---|---|---|
 | ||||
| ||||
| ||||
| ||||
| ||||
| - | |||
| ||||
| ||||
| ||||
| Average | ||||
| Weighted average by Cap. |
Turnover
Earnings Per Share (EPS)
Data source:
Lakefront Biotherapeutics NV(LKFT)
EBIT
Dividend / Share (DPS)
Data source:
Lakefront Biotherapeutics NV(LKFT)
Cash or Net Debt
- Stock Market
- Stocks
- LKFT Stock
- G1LP34 Stock
- Consensus Galapagos NV
- Estimates Revisions
Select your edition
All financial news and data tailored to specific country editions
